<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03356860</url>
  </required_header>
  <id_info>
    <org_study_id>ONCOGHdC2015_01</org_study_id>
    <nct_id>NCT03356860</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.</brief_title>
  <acronym>B-IMMUNE</acronym>
  <official_title>A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grand Hôpital de Charleroi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grand Hôpital de Charleroi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has a phase Ib and a phase II part.&#xD;
&#xD;
        -  The phase Ib aims to evaluate the safety and tolerability of durvalumab in combination&#xD;
           with a dose- dense EC regimen in a neoadjuvant setting for early breast cancer.&#xD;
&#xD;
        -  The phase II aims to explore the efficacy of durvalumab in combination with a dose-dense&#xD;
           EC regimen in a neoadjuvant setting for early breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>74 weeks</time_frame>
    <description>(serious) adverse event will be recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathological response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of complete pathological responses will be evaluated as a surrogate endpoint to evaluate efficacy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Luminal B</condition>
  <arm_group>
    <arm_group_label>Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.&#xD;
Durvalumab will be administered at 1500 mg IV at week 14 and week 18.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80mg/m2 IV weekly from week 1 to week12</description>
    <arm_group_label>Durvalumab</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>90 mg/m2 IV Q 2 weeks from week 14 to week 20</description>
    <arm_group_label>Durvalumab</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Farmorubicine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m2 IV Q 2 weeks from week 14 to week 20</description>
    <arm_group_label>Durvalumab</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab 1500 mg IV at week 14 and 18</description>
    <arm_group_label>Durvalumab</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent and any locally-required authorization (EU Data Privacy&#xD;
             Directive in the EU) obtained from the subject prior to performing any&#xD;
             protocol-related procedures, including screening evaluations&#xD;
&#xD;
          -  Female and male aged &gt; 18 years at time of study entry.&#xD;
&#xD;
          -  Patient has T1-T4 any N, M0, operable breast cancer&#xD;
&#xD;
          -  Confirmed invasive ductal, lobular, mixed or medullary breast carcinoma&#xD;
&#xD;
          -  TNBC defined as negative oestrogen and progesterone receptors as per local laboratory&#xD;
             testing and negative HER2 defined as negative ISH test or an IHC status of 0 or 1+ as&#xD;
             per local laboratory testing&#xD;
&#xD;
          -  Luminal B HER2 negative BC defined as positive oestrogen and/or progesterone&#xD;
             receptors, a negative HER2 defined as negative ISH test or an IHC status of 0 or 1+ as&#xD;
             per local laboratory testing and a Ki67 &gt; 14%.&#xD;
&#xD;
          -  World Health Organisation (WHO) performance status of 0 or 1&#xD;
&#xD;
          -  Adequate normal organ and marrow function as defined below:&#xD;
&#xD;
               1. Haemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (&gt; 1500 per mm3)&#xD;
&#xD;
               3. Platelet count ≥ 100 x 109/L (&gt;100,000 per mm3)&#xD;
&#xD;
               4. Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).&#xD;
&#xD;
               5. AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit&#xD;
&#xD;
               6. Serum creatinine CL&gt;40 mL/min&#xD;
&#xD;
          -  Normal cardiac function must be confirmed by ECG and cardiac function assessed by US&#xD;
             imagery, radionucleotide ventriculography or MUGA, 4 weeks prior to randomization.&#xD;
             Results must be above the normal limit of the institution&#xD;
&#xD;
          -  Women must either be postmenopausal or must have a negative serum pregnancy test 14&#xD;
             days upon study entry.&#xD;
&#xD;
          -  For a woman of childbearing potential, an effective method of birth control must be&#xD;
             employed.&#xD;
&#xD;
          -  Men must use 2 effective contraceptive measures or male sterilization with female&#xD;
             partners of childbearing potential or pregnant female partners, or they must remain&#xD;
             abstinent during the treatment period and for at least 6 months after the last dose of&#xD;
             the study treatment.&#xD;
&#xD;
          -  Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
          -  Subject accepts planned biological samples collection and their use for the trial&#xD;
             propose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study&#xD;
&#xD;
          -  Previous enrolment in the present study&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 4 weeks&#xD;
&#xD;
          -  Patient has locally recurrent or metastatic invasive BC&#xD;
&#xD;
          -  History of another primary malignancy except for:&#xD;
&#xD;
               1. Malignancy treated with curative intent and with no known active disease ≥5 years&#xD;
                  before the first dose of study drug&#xD;
&#xD;
               2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               3. Adequately treated carcinoma in situ without evidence of disease eg, cervical&#xD;
                  cancer in situ or BC in situ.&#xD;
&#xD;
          -  Patient has received any systemic therapy (e.g. chemotherapy, targeted therapy,&#xD;
             immunotherapy) or radiotherapy for current breast cancer disease&#xD;
&#xD;
          -  Whatever the indication, receipt of a last dose of anti-cancer therapy (chemotherapy,&#xD;
             immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor&#xD;
             embolization, monoclonal antibodies, other investigational agent) ≤ 21 days prior to&#xD;
             the first dose of study drug&#xD;
&#xD;
          -  Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab&#xD;
&#xD;
          -  Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous&#xD;
             immunotherapy agent, or any unresolved irAE &gt;Grade 1&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or&#xD;
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of&#xD;
             prednisone, or an equivalent corticosteroid&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from&#xD;
             electrocardiograms (ECGs) using Fridericia's Correction&#xD;
&#xD;
          -  Known or suspected congestive heart failure (&gt;NYHA I) and / or coronary heart disease,&#xD;
             angina pectoris requiring antianginal medication, previous history of myocardial&#xD;
             infarction, evidence of transmural infarction on ECG, uncontrolled or poorly&#xD;
             controlled arterial hypertension (i.e. BP &gt;140 / 90 mm Hg under treatment with two&#xD;
             antihypertensive drugs), rhythm abnormalities requiring permanent treatment,&#xD;
             clinically significant valvular heart disease.&#xD;
&#xD;
          -  Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects&#xD;
             with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within&#xD;
             the past 2 years) are not excluded.&#xD;
&#xD;
          -  Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,&#xD;
             ulcerative colitis)&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  History of allogeneic organ transplant&#xD;
&#xD;
          -  History of hypersensitivity to durvalumab or any excipient&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active&#xD;
             bleeding diatheses, any subject known to have evidence of acute or chronic hepatitis&#xD;
             B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirements or compromise the&#xD;
             ability of the subject to give written informed consent&#xD;
&#xD;
          -  Subjects with uncontrolled seizures.&#xD;
&#xD;
          -  Known history of active tuberculosis&#xD;
&#xD;
          -  Anticipation that a live attenuated vaccine will be required during the period from 30&#xD;
             days prior to the first planned durvalumab administration (e.i. week 18 and week 14&#xD;
             after study entry for the phase Ib and phase II respectively) to 5 months of&#xD;
             durvalumab discontinuation. Influenza vaccination (inactivated forms only but not live&#xD;
             attenuated forms) should be given during influenza season only (approximately October&#xD;
             to March).&#xD;
&#xD;
          -  Female subjects who are pregnant, breast-feeding or female patients of reproductive&#xD;
             potential who are not employing an effective method of birth control&#xD;
&#xD;
          -  Men with female partners of childbearing potential or pregnant female partners who are&#xD;
             not employing an effective method of birth control&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of study treatment or interpretation of patient safety or study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Carrasco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GHdC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Luc Canon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GHdC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Duhoux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc (UCL)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Carrasco, MD, PhD</last_name>
    <phone>71104732</phone>
    <phone_ext>0032</phone_ext>
    <email>b-immunetrial_support@oncobase.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Carrasco, MD, PhD</last_name>
      <email>javier.carrasco@ghdc.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1320</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois Duhoux, MD, PhD</last_name>
      <email>francois.duhoux@uclouvain.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>anti-PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

